Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Training program for correct administration of Cardioplexol during cardiac surgery
2018-002311-10Phase 3Completed
- Sponsor
- Swiss Cardio Technologies
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Cardioplexol in coronary arteriosclerosis and Cardiac valve disease (VHD), sponsored by Swiss Cardio Technologies. Primary endpoint: Major deviations from Cardioplexol application protocol. Started Jul 2018; status: completed.
02
Drugs
Cardioplexol
03
Conditions
coronary arteriosclerosisCardiac valve disease (VHD)
Beyond the preview
Go deeper on 2018-002311-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002311-10.